Strategic Intelligence on China’s Health Policy, Coverage, and Financing System
Interpreting policy signals, examining financing mechanisms, and assessing their commercial and strategic implications.
Published in Caixin and China Reform Magazine
Engagement Paths
Access360
Ongoing strategic intelligence platform
Masterclass
Executive strategic foundation for China access decision-making
Strategy Session
Asset-specific strategic trade-off and executive alignment session
Selected Strategic Analyses
A curated selection of recent strategic analyses interpreting policy signals, examining financing mechanisms, and assessing implementation dynamics shaping medical technology access across China’s multi-layer coverage system.
China’s Healthcare System Is Reorganizing: What It Means for Manufacturers
An analysis of how evolving care pathways and shifting payment dynamics are reshaping how access is secured and how value is realized—redefining the commercial logic for manufacturers operating in China’s system.
Intelligence Briefing | April 2026
RWE and the Quiet Rewiring of China’s Reimbursement System
An analysis of how recent policy releases are embedding real-world evidence into China’s pricing, reimbursement, and procurement governance—gradually transforming RWE from an evaluation tool into a structural policy instrument across the lifecycle of medical technologies.
Intelligence Briefing | March 2026
From Reference Tool to Operating Model: A Roadmap for China’s C-List
A strategic roadmap outlining how China’s Commercial Innovative Drug List can evolve from a formulary reference into a coordinated operating model across financing layers.
Intelligence Briefing | January 2026
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
A premier interpretive briefing on China’s biosimilar volume-based procurement (VBP)—exploring emerging rules, pricing dynamics, and early signals of downstream commercial impact.
Intelligence Briefing | December 2025
NFRAs’ Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
An interpretive briefing on the NFRAs’ Guiding Opinions and their implications for China’s multi-layer coverage framework and financing dynamics.
Intelligence Briefing | November 2025
NHSA Strengthens Control Over Outpatient Spending
Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
Intelligence Briefing | December 2024
Access360 membership is available for individual professionals and institutional teams.
Explore Membership Options.